Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

OnCusp: Bing Yuan’s newco to provide bridge from innovation to MNC

Emerging Company Profile: OnCusp launches to license, develop early stage cancer therapies before out-licensing assets to MNCs

July 2, 2021 1:34 AM UTC

Former CStone and Merck & Co. dealmaker Bing Yuan and his OnCusp co-founders are using their early stage drug hunting skills to identify cancer assets from the U.S. and China that will appeal to MNCs, and guide them to POC before out-licensing. 

OnCusp Therapeutics emerged from stealth on Tuesday with a $25 million seed round led by Sequoia Capital China and Biotrack Capital, and a focus on making deals to bring in innovative cancer therapies, including antibody-drug conjugates (ADCs) and multispecific therapies. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article